Abstract 195P
Background
Ferroptosis is a type of programmed cell death dependent on iron metabolism distinct from necrosis and apoptosis. In pancreatic ductal adenocarcinomas (PDAC), studies have noted that ferroptosis signatures are also associated with survival. However, no studies have attempted to find histological correlates which might suggest a ferroptosis process occurring.
Methods
PDACs from the Cancer Genome Atlas (TCGA) Pan-Cancer were used. Clinicopathological, DNA, histological slides, and mRNA expression data were extracted with the GDC Data Transfer Tool. A scree plot was generated to determine the optimal number of clustering groups based on ferroptosis molecular signatures. A K-means clustering approach was used in STATA. Groups of less than 5 patients were excluded. The ferroptosis-based clusters were correlated to clinical, histological, molecular, and survival parameters. Gene Set Enrichment Analysis (GSEA) was also performed by identified cluster. An adjusted α = 0.05 for statistical significance was used for all tests.
Results
175 PDAC cases were used from the TCGA. Optimal K-means clustering identified 4 distinct ferroptosis signature-based PDAC groups, which differed in gene expression. Group 1 (n=47) showed improved overall survival by log-rank analysis versus other 3 groups (p<0.05). There was no significant difference in age, sex distribution, tumor grade, necrosis or staging between Group 1 and other groups. Over-expressed genes in ferroptosis-based group 1 include MAP3K14, TNFAIP3, CYGb; underexpressed genes in Group 1 include EMC2, ZFAS1, CYP4F8. GSEA showed downregulation of EET, DHET and HETE synthesis, and upregulation of RNA metabolism, cell cycle and mitotic activity in Group 1 vs other 3 groups.
Conclusions
A comprehensive multimodal approach to ferroptosis expression signatures highlights a clinical impact on overall survival. However, after post-hoc analysis by two pathologists, no histological marker was identified to be significantly associated with ferroptosis signatures. Genes involved in group 1 modulate nF-κB signaling, target lipid peroxidation, and inhibit GPX4 function. Further ancillary testing of ferroptosis pathway in PDACs is warranted.
Editorial acknowledgement
Legal entity responsible for the study
Vincent Quoc-Huy Trinh.
Funding
Fonds de recherche Santé Québec.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract